Printer Friendly

Lower significant rate of etomidate-induced myoclonus for procedural sedation in emergency department of a tertiary care hospital.

INTRODUCTION

In emergency settings, a set of drugs have been used in patients for procedural sedation, [1] of which etomidate is the choice that can be used as sedative hypnotic agents. [2] Etomidate is a carboxylated imidazole [3] that depress central nervous system through gamma-aminobutyric acid. [4] Due to its quick action, low profile for cardiovascular risk, minimal respiratory depression, and reliable sedation, etomidate is optimal for procedural sedation in the emergency department (ED). [5] Etomidate can act as a defensive role in cerebral and myocardial ischemia, easy dosing profile, limited ventilation suppression, and decreased the release of histamine, [6] and for patients who are hemodynamically unstable, etomidate is the inducting agent. [7] In traumatic brain injury patients, it reduces intracranial pressure and maintains normal arterial pressure [8]

Etomidate is highly protein bound in blood plasma, and it is metabolized by hepatic and plasma esterases. [9]

The most common adverse effects of etomidate are myoclonus and adrenal suppression. Others include nausea, vomiting, and pain at the injection site. [10] In both anesthesia and emergency literature, myoclonus with etomidate induction and sedation in ED has been described. In ED sedation doses, the reported incidence of etomidate-induced myoclonus is about 33%. [1]

Our study is to quantify that the incidence and people with etomidate-induced myoclonus are less than the reported percentage in the patients.

MATERIALS AND METHODS

Here, we conducted a prospective study for 6 months between June 2016 and December 2016 at Amrita Institute of Medical Sciences, Kochi, a 1800-bedded tertiary care hospital. Patients who were subjected for sedation in the ED with etomidate were enrolled for the study. In our ED, the procedure was undertaken at the vigilance of the emergency physician. In the meantime, the patients cardiac, pulse oximetry, blood pressure, and end-tidal carbon dioxide monitoring were monitored according to the guidelines in the ED.

The data were collected and compiled using Microsoft excel. Demographics were recorded on each patient. The dose of etomidate was noticed. The observed result was the presence of the myoclonus. The informations were tabulated on the data sheet.

Selection and Description of Participants

All patients who were subjected for procedural sedation with etomidate are included in the study. Those who were pregnant, having neuromuscular disorder, having adverse reaction with etomidate, and who are unable to give the consent form were excluded from the study (Table 1).

Technical Information

In this study, patients who developed myoclonus after the administration of etomidate during procedural sedation in the ED. The severity of myoclonus developed in patients after the administration of etomidate was measured using the scale (Table 2). Cardiac, blood pressure, and pulse oximetry were recorded according to the guidelines of the ED.

Ethics

The data collection was done after the authorization from the research committee. The patients were chosen according to the exclusion and inclusion criteria.

Statistics

The percentage of patients with respect to various variables was computed, namely, age, sex, gender distribution, mean total of etomidate dose, severity of myoclonus, and time to onset of myoclonus after etomidate administration. Statistical significance was calculated using P value.

RESULTS

In our study of 166 (116 male and 50 female) patients, 4 (1 male and 3 female) patients developed myoclonus with the administration of etomidate during procedural sedation in ED. The P value obtained for this is 0.04765 (the result is significant at <0.05) which shows that study is statistically significant.

This study focuses on the lower significant rate of etomidate-induced myoclonus for procedural sedation in a tertiary care hospital. Other ED studies had shown that occurrence of myoclonus with etomidate ranges from 7 to 20%. The studies also showed that the occurrence of myoclonus is dose dependent (Table 3).

DISCUSSION

Yates et al. showed that myoclonus had developed about 75% of the patients. In our study, about 2.4% (4 out of 166 patients) of the patients developed myoclonus with etomidate which is of being in minor degree during procedural sedation in ED. The severeness of myoclonus was assessed using the scale as per Table 2. Patients who had developed mildto-moderate myoclonus in the ED during sedation was less compared to other studies.

Several studies by Doenicke et al. [11] and Stockham et al. [12] show that the myoclonus can be abolished with administration of premedications such as benzodiazepines or Stockham et al. [12] In our study, we did not administered any premedications before the administration [13] of etomidate.

Furthermore, we were specifically looking for myoclonus which has increased our sensitivity to detect whether it happened or not. The rate of myoclonus was less, and the success of procedural sedations determined that the etomidate can be administered as a sedative agent for the patient for procedural sedation.

Since etomidate-induced myoclonus was less compared to other studies, it can be administered as sedative agent in ED for procedural sedations. Our study was carried out to show that the etomidate-induced myoclonus is less compared to the studies conducted by Yates et al. [3]

CONCLUSION

From this, we came to the conclusion that the incidence to occur myoclonus with the administration of etomidate is less when compare with other ED studies.

REFERENCES

[1.] Van Keulen SG, Burton JH. Myoclonus associated with etomidate for ED procedural sedation and analgesia. Am J Emerg Med. 2003;21(7):556-8.

[2.] Di Liddo L, D'Angelo A, Nguyen B, Bailey B, Amre D, Stanciu C. Etomidate versus midazolam for procedural sedation in pediatric outpatients: A randomized controlled trial. Ann Emerg Med. 2006;48(4):433-40, 440.e1.

[3.] Yates AM, Wolfson AB, Shum L, Kehrl T. A descriptive study of myoclonus associated with etomidate procedural sedation in the ED. Am J Emerg Med. 2013;31(5):852-4.

[4.] Vinson DR, Bradbury DR. Etomidate for procedural sedation in emergency medicine. Ann Emerg Med. 2002;39(6):592-8.

[5.] Falk J, Zed PJ. Etomidate for procedural sedation in the emergency department. Ann Pharmacother. 2004;38(7-8):1272-7.

[6.] Hohl CM, Kelly-Smith CH, Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: A systematic review. Ann Emerg Med. 2010;56(2):105-3.e5.

[7.] Sivilotti ML, Filbin MR, Murray HE, Slasor P, Walls RM. NEAR investigators. Does the sedative agent facilitate emergency rapid sequence intubation? Acad Emerg Med. 2003;10(6):612-20.

[8.] Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: A one-year study of 610 tracheal intubations. Ann Emerg Med. 1998;31(3):325-2.

[9.] Available from: https://www.en.wikipedia.org/wiki/Etomidate.

[10.] Available from: http://www.uptodate.com/contents/etomidate-druginformation?source = search_ result&search=etomidate&selectedTitle=1%7E98#F169113.

[11.] Doenicke A, Kugler J, Penzel G, Laub M, Kalmar L, Killian I, et al. Cerebral function under etomidate, a new non-barbiturate i.v. hypnotic. Anaesthesist. 1973;22(8):357-66.

[12.] Stockham RJ, Stanley TH, Pace NL, Gillmor S, Groen F, Hilkens P. Fentanyl pretreatment modifies anaesthetic induction with etomidate. Anaesth Intensive Care. 1988;16(2):171-6.

[13.] Rajan S, Devapal D, Kumar L. Effectiveness of oral ephedrine in prevention of hypotension following Spinal. Anaesthesia. 2015;11(1):17-21.

Ashly Alexander Fernandez, Neethu C M

Department of Pharmacy Practice, Amrita Vishwavidyapeetham University, Kochi, Kerala, India

Correspondence to: Neethu C M, E-mail: neethucm@aims.amrita.edu

Received: August 03, 2017; Accepted: August 17, 2017

DOI: 10.5455/njppp.2018.8.0728417082017
Table 1: Demographics

Parameters                     Frequency

Number of patients              166
Number of procedural sedation   166
Age (mean), y                    42
Male                            116
Female                           50
Weight (mean), kg                79
Height (mean), in                67

y: Years, kg: Kilogram, in: Inches

Table 2: Myoclonus scale used to assess the degree of myoclonus

0 - No myoclonus
1 - Mild myoclonus: Minor tremors or myoclonus of 1 extremity
2 - Moderate myoclonus: Myoclonus of 2-3 extremities
3 - Severe myoclonus: Involvement of all extremities or myoclonus
severe enough to require extremity stabilization or premature
termination of procedure

Table 3: Etomidate-induced myoclonus

Parameters                                   Value

Initial etomidate dose (mean) (mg/kg)        0.13
Mean total etomidate dose                    0.15
Total number experiencing myoclonus          4
Mild                                         2
Moderate                                     1
Severe                                       1
Time to onset of myoclonus after etomidate  52
administration (mean), s
Duration of myoclonus (mean), s             90
COPYRIGHT 2018 Dipika Charan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:SHORT COMMUNICATION
Author:Fernandez, Ashly Alexander; Neethu, C.M.
Publication:National Journal of Physiology, Pharmacy and Pharmacology
Article Type:Clinical report
Date:Feb 1, 2018
Words:1363
Previous Article:Variation in erythrocyte and leukocyte counts before and after normal vaginal delivery.
Next Article:Rabeprazole-induced acute interstitial nephritis: A case report.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters